Research

Life Sciences & Biotechnology

Title :

Targeting the DNAG-DNAB interaction in Mycobacterium tuberculosis to identify and validate suitable small molecule inhibitors

Area of research :

Life Sciences & Biotechnology

Focus area :

Mycobacterium tuberculosis

Principal Investigator :

Dr. Manju Yasoda Krishnan, Scientist, Department of Microbiology, Central Drug Research Institute (CDRI), Lucknow, Uttar Pradesh

Timeline Start Year :

2016

Contact info :

Details

Total Budget (INR):

 37,80,000

Organizations involved

Implementing Agency :

Department of Microbiology, Central Drug Research Institute (CDRI), Lucknow, Uttar Pradesh

Funding Agency :

Science and Engineering Research Board (SERB), Department of Science & Technology (DST), Govt. of India

Related Research

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis
A multilayered regenerative scaffold engineered to heal deep wound by mimicking anatomical architecture of natural tissue
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
A randomized, double-blind, placebo and active controlled, multicenter, phase 3 study to access the efficacy and safety of Filgotinib administered for 52 weeks in combination with Methotrexate (MTX) to subjects with moderately to severely active rheumatoid arthritis, who have an inadequate response to methotrexate
Aldose reductase (AR) mediated aberrant molecular changes in coincident diabetes and cancer: Effect of dietary AR inhibitors